Strengthening Immunization Quality Using Old Survey Data: Analytical Evidence from the 2014 Cameroon Multiple Indicator Cluster Survey (MICS)

Abstract

Objective: Vaccination coverage in Cameroon remains below targets due to missed opportunities for vaccination (MOV) and delays in timely immunization. This study used data from the 2014 Multiple Indicator Cluster Survey (MICS) to assess vaccination timeliness and MOV, with the goal of proposing a reusable analytic framework for future surveys. Methods: Children aged 12 - 35 months with documented vaccination dates were included. Vaccine doses were classified as early, timely, or delayed based on the national immunization schedule. Timeliness-to-completeness with their 95% confidence intervals (IC) measured how many children were protected on time. Missed opportunity for simultaneous vaccines (MOSV) was defined as the failure to receive one or more vaccine due doses during a health system contact. Uncorrected missed opportunity for vaccination (uncorrected MOV) was defined as a child who missed one or more due vaccine doses during a contact and did not subsequently return to receive the missed vaccine(s). All uncorrected MOVs refer to children who failed to receive all due vaccines that were missed during eligible contacts. Analyses included descriptive statistics, meta-analysis of MOV proportions, stratified comparisons, and modeling based on the “All uncorrected MOSV” status with a stepwise logistic regression analyses completed with a decision tree classification. Results: Of 1447 children (65.3% of cards ownership), 66.1% (95% CI = 63.6 - 68.5) were fully vaccinated among which only 11.3% (95% CI = 9.4 - 13.5) received vaccines on time. Timeliness was below 80% for all antigens, from 34.7% (BCG) to 61% (Penta1). Timely and completeness for specific doses ranged from 27% to 52%. MOV for simultaneous vaccines (MOSV) prevalence was 90% (95% CI = 84 - 94) nationally, among which 61% (95% CI = 53 - 69) of children had ALL uncorrected MOSV. MOV was significantly more frequent in rural areas and varied by maternal education, wealth, region, and care use. Dose specific MOV ranged from the lowest of 4% (56/1413) for BCG, to the highest of 53.04% for the yellow fever, to 57.1% for PCV vaccines. A significant difference in MOV between sexes indicates gender-related inequities. Conclusion: Although based on an older survey, this study demonstrates a methodology for analyzing vaccination data, encompassing both timeliness and combined timeliness-completeness, as well as missed opportunities for vaccination (MOV). The MOV analysis highlights equity gaps and underscores the importance of community-driven, gender-sensitive strategies to strengthen vaccine delivery. Additionally, the observed association between maternal experience of domestic violence and the occurrence of missed opportunities for simultaneous vaccination warrants further investigation.

Share and Cite:

Whegang Youdom, S. and François, Z. (2026) Strengthening Immunization Quality Using Old Survey Data: Analytical Evidence from the 2014 Cameroon Multiple Indicator Cluster Survey (MICS). Health, 18, 191-220. doi: 10.4236/health.2026.182014.

1. Background

Vaccination remains one of the most effective public health interventions for reducing childhood morbidity and mortality, especially in low- and middle-income countries [1] [2]. However, achieving high overall coverage is not sufficient; ensuring that children are vaccinated on time and at every eligible opportunity is equally critical to sustaining disease control and elimination [3] [4]. Yet, despite relatively high overall coverage reported in national surveys, challenges such as Missed Opportunities for Vaccination (MOV) and untimely vaccination continue to hinder the full potential of these programs [5] [6].

A missed opportunity for vaccination (MOV) occurs when a person who is eligible for vaccination (with no true contra-indications) has contact with health services but does not receive all of their needed vaccines [3] [5]. MOVs are commonly observed when a person attends health services for curative care due to inadequate integration of curative and preventive services. They may also occur when a person attends for vaccination. If they receive some but not all vaccines for which they are eligible, we use the term missed opportunity for simultaneous vaccination (MOSV) according to established guidelines and literature [7] [8].

Vaccination timeliness, on the other hand, refers to the administration of vaccines within the recommended age range, ensuring optimal immune response and protection when children are most vulnerable [9] [10]. Both concepts are increasingly recognized as key quality indicators of immunization programs and are essential for achieving optimal protection in children during periods of greatest vulnerability [8] [11]. In addition, among those key performance indicators, timeliness-and-completeness is crucial for identifying gaps, preventing outbreaks, and supporting better planning of immunization activities. According to the World Health Organization (WHO), an effective surveillance system requires that reports be submitted on time and in full to enable timely and appropriate public health responses [12] [13].

Although studies focusing on MOV and timeliness have increased globally [14]-[22], relatively few have analyzed these indicators in Cameroon in detail. Notable recent efforts include, the analysis of the 2018 Cameroon Demographic and Health Survey (DHS) which reported an MOSV of 75.1% among children aged 12 - 23 months, with uncorrected MOSV at 67.4%, and the highest rates were seen for the Yellow Fever vaccine [20]. A subnational assessment reported an MOV rate of 23.8%, and linked missed doses to both caregiver-related and systemic factors, including poor health worker practices [17].

However, despite the relevance of these indicators, there has been limited analysis of MOV and timeliness using earlier datasets such as the 2014 Cameroon Multiple Indicator Cluster Survey (MICS). Indeed, MICS surveys offer child-level immunization data, including vaccination dates and card ownership, yet MOV and timeliness remain underreported in official outputs.

MOVs have most often been assessed by studies based at health facilities [6] [17] [21] [23] [24]. Such studies have the advantage of allowing investigation of the causes of MOVs but are limited in their generalizability, since they only include people who visit health facilities, and exclude children who don’t seek care, are marginalized, or live in remote areas. By contrast, MOSVs can be assessed by appropriate analyses of household surveys that collect information on dates of each vaccine received, allowing estimation of their impact at the population level on coverage and on median age at vaccination [8] [20] [25] [26]. DHS as well as MICS, offers survey data, and plays a great role in the identification of immunization service quality indicators, standing as a mean of achieving Sustainable Development Goal (SDG) i.e. SDG3: Ensure healthy lives and promote well-being for all at all ages, which directly includes immunization, maternal and child health, and disease prevention. Methods for analyzing MOV from survey have been documented and first analyses and demonstration highlighted from some surveys [8] [26] [27].

Although several countries have not yet integrated MOVs (Missed Opportunities for Vaccination) into their programs, this methodology is still not widely adopted.

MOV assessment is not listed among the standard analyses for a vaccination coverage survey but is listed as an additional analysis [8]. Neither DHS nor MICS reports MOV outcomes routinely. Nigeria was a notable exception, having included analyses of missed opportunities for simultaneous vaccination (MOSV) in its main MICS reports in 2016 and 2021 [7] [26]. Otherwise, analyses of MOV or MOSV using DHS and MICS data have been conducted exclusively through secondary data analysis [28]. This means that the programmatic insights gained from examining MOSVs are typically made available to stakeholders after the release of the main vaccination coverage results. Since 2021, Cameroon has strengthened its commitment to addressing population health needs [25] [29] [30]. In the area of immunization, a key strategy supporting this effort is the triangulation of survey data to better identify children eligible for vaccination and those missed by routine services. MICS data, like DHS and other household survey sources, enable the tracking of performance indicators such as zero-dose status and dropout rates, thereby providing critical evidence to guide immunization planning and program improvement.

To complete this picture, quality indicators are also included namely, vaccination timeliness, timeliness and completeness of reporting, and missed opportunities for vaccination (MOVs). Their estimates provide insight into the number of eligible children who remain unvaccinated, as well as the frequency of missed doses. Other MOV-related indicators include visits that resulted in missed opportunities.

However, analyses of timeliness indicators and MOV using MICS data have been largely absent from both peer-reviewed literature and policy reports in Cameroon. This study therefore seeks to fill this gap by conducting a comprehensive analysis of vaccination timeliness and missed opportunities for vaccination using the Cameroon MICS 2014 dataset. By identifying patterns and associated factors, the study aims to apply and illustrate a combination of statistical methods for analyzing vaccination timeliness and missed opportunities for vaccination (MOV) using data from the MICS Cameroon 2014 survey. The objective is to demonstrate how retrospective datasets can be used to develop analytical approaches that inform the interpretation of future survey results and support more effective planning of immunization services in similar settings.

2. Methods

2.1. What Is Known from MICS5 2014

The Multiple Indicator Cluster Survey (MICS 5) of Cameroon was conducted in 2014 by the National Institute of Statistics in collaboration with the Ministry of Public Health, as part of the global MICS program. Technical support was provided by the United Nations Children’s Fund (UNICEF) [31]. Based on the standard MICS5 vaccination module and Cameroon’s EPI schedule, the following vaccines were assessed in the survey: BCG (Bacillus Calmette-Guérin); Polio vaccines: Oral Polio Vaccine at birth (OPV), Pentavalent vaccine (DTP-HepB-Hib1-3), Pneumococcal Conjugate Vaccine (PCV) (e.g., PCV1-3), Measles-containing vaccines: Measles-Rubella (MR), and vitamin A supplementation administered between 6 and 11 months, and every 6 months. The 2014 MICS reported 67% of children aged 12 to 23 months with vaccination records seen [31].

2.2. Methodological Framework

2.2.1. Data Filtering and Selection Process

We combined datasets from households, women and children to extract all necessary child’s characteristics. All children aged 12 to 35 months who were alive at the time of the survey were selected.

Vaccination dates indicating a year of birth later than 2014 were classified as missing and removed from the analysis. Additionally, new categories were created for cases where the recorded vaccination day exceeded 31. In these instances, the vaccination record was typically represented by a check mark, a caregiver’s recollection, a “don’t know” response, or was simply absent. These details played an important role in calculating missed opportunities for vaccination (MOV), as they helped to identify children with valid vaccination dates (day, month, and year).

2.2.2. Data Analysis

We provided percentage of children with vaccination cards, zero-dose children, and percentage of children in the various sources of vaccination (cards, tick-mark, and recall). Subsequently, we selected children with vaccination cards containing at least one recorded vaccination date; this group served as the denominator for calculating cumulative vaccination coverage, vaccination timeliness indicators, and timely-and-complete indicators. Vaccination timeliness was defined in three distinct categories: early, on time and delay. Early doses are those administered before the minimum age of vaccination; on time administration referred to doses given within the window of opportunity i.e., the child reached the minimum age and was vaccinated before the minimum age and 30.5 days (maximum age); and delayed doses are those provided after the maximum age (Table S1).

Vaccination completeness was calculated as the percentage of children who received BCG, OPV0-3, Penta1-3, PCV1-3, measles, and yellow fever. Timely-and-complete indicators were defined as those who were completely vaccinated and received the vaccine on time. The percentage of this indicator was calculated for unique dose, and doses in a series (Penta1-3; OPV1-3, Pcv1-3). identifying how many children were protected on time, which is crucial for early protection against vaccine-preventable diseases. For Penta3, confidence intervals accompanied percentage vaccinated on time for each region.

An overall estimate of MOSV, regardless of characteristics, was calculated, along with an adjusted value (estimated using the traditional random-effects meta-analysis of proportions) [32], and its associated 95% confidence interval. Then, these indicators were stratified by age group, vaccine dose, and other characteristics such as the child’s sex, region of origin, place of residence, mother’s education level, place of birth of the child, household wealth quintile, and others such as skilled birth attendance and prenatal characteristics. Sub-indicators of MOSV included uncorrected MOSV, and all corrected MOSV computed from the total sample of children who experienced at least one MOV for any vaccine. Uncorrected MOSV refers to the proportion of children who experienced at least one MOV for any vaccine, and who remained unvaccinated for those missed doses by the time the survey began. In contrast, all corrected MOSV applies to any child who experienced an MOSV and had time to receive all missed vaccine doses before the survey started. Additionally, sub-indicator (that can be deduced from the three others) included “Some BUT not all MOV corrected”, which is the proportion of children who experienced at least one MOSV, but did not receive all previously missed doses before the survey commenced [8]. Furthermore, the frequency of missed doses was calculated as recommended by WHO 2018, by assessing the number of vaccination dates where children experienced simultaneous missed opportunities for vaccination (MOV). Additionally, the percentage of vaccination dates with missed doses, as well as the frequency of visits resulting in MOV, were analyzed.

We included variables linked to domestic violence, hypothesizing that mothers facing challenges like missed opportunities for vaccination (MOSV) of their children might also be experiencing mental health issues [33]. To construct the domestic violence score, we applied multiple component analysis (MCA) to a set of ordinal variables capturing women’s reported experiences of intimate partner violence, including emotional, physical, and sexual violence (e.g., humiliation, threats, physical assault, forced sexual acts). All variables were coded consistently so that higher values indicated greater exposure to violence. MCA was used to reduce these correlated indicators into a single composite score representing overall intensity of domestic violence. The first principal component, which explained the largest proportion of variance across items, was retained as the violence score. This continuous score was then categorized into quartiles to facilitate interpretation and to allow association with other qualitative variables: higher quartiles indicated increasing levels of exposure to domestic violence. A binary score was also considered by splitting the score using the median value.

An essential indicator highlighted was the proportion of children with uncorrected MOSV, representing the percentage of children who missed one or more vaccines and remained unvaccinated by the time the MICS survey commenced. This indicator is crucial as it reveals the part of the population that vaccination campaigns have not yet reached. Qualitative variables were presented as effective frequency with proportions; quantitative variables were described using median and interquartile range. Pearson Chi-squared test or Fisher exact test were used to compare proportions, and Wilcoxon-Mann-Whitney test for comparing group means.

To better understand the factors contributing to missed opportunities for vaccination, uncorrected MOSV status was used as the dependent variable, with a step-by-step logistic regression guiding the process of variable selection. Independent variables were child, maternal, and household characteristics. Significant predictors identified during this process were then incorporated into a decision tree model [34]. Additionally, interaction effects with the child’s sex were evaluated to determine any possible influence before integrating the variables into the decision tree. This gender-sensitive approach enabled an analysis of whether risk profiles and decision-making pathways differed between boys and girls. This, in turn, helped to identify potential gender-related disparities in vaccination coverage.

All MOV and sub-sequent analyses were coded using R version 4.5.0 following VCQI specification guidelines [27] [35].

2.3. Results

2.3.1. Description of the Sample Studied

A detailed flowchart of the selection process is presented in Figure S1. In total, 2214 children aged 12 to 35 months were surveyed, of whom 1447 (373 + 1074 = 51.8%) had vaccination records with at least one documented date i.e., 65.3% of card ownership (95% CI = 63.3 - 67.3), suggesting a total of 767 (34.7%) of children never vaccinated (zero-dose) (Table S1). In this targeted sample, the sample size varied by antigen from 1115 for yellow fever to 1403 for OPV1, indicating that 2.2% not vaccinated for yellow fever and 0.22% for OPV1 (Table S2).

2.3.2. Cumulative Coverage

The cumulative coverage curves presented in Figure S2 are based exclusively on children whose vaccination cards were seen and included dates, which typically represent the most reliable source of immunization data. As expected, overall coverage levels appear relatively high across most antigens. Birth vaccines such as BCG and OPV0 show a steep and early rise in coverage, indicating that these doses are generally administered on time. However, for multi-dose vaccines such as OPV, PENTA, and PCV, timeliness tends to decline progressively with each additional dose, as reflected by the flattening of the curves.

More striking delays are observed for MCV1 and Yellow Fever vaccines. Although MCV1, expected at 9 months, eventually reaches close to 65% - 70% coverage (Figure S2), the gradual slope suggests delays in timely administration. Yellow Fever coverage remains notably lower, with slow uptake and a final coverage under 75% by 12 months. These patterns highlight the importance of considering timeliness in addition to coverage, especially when using high-quality data from children with dated cards. The analysis underscores how even in settings where documentation is available, delayed vaccinations and missed opportunities persist emphasizing the value of integrating timeliness metrics into survey-based assessments.

2.3.3. Timeliness and Completeness Indicators

1) Vaccination timeliness among children 12 to 35 months

Children were receiving vaccine doses as recommended. However, there were instances of both early and delayed doses. Among the children who received the vaccines, on time fell short of the percentage of card ownership, ranging from a high of 61.7% for Penta1 to a low of 34.7% for BCG, suggesting the highest proportion of delayed doses for BCG, reaching 65.3% (Figure 1). Timeliness for the third dose of the pentavalent vaccine (Penta3) varied considerably across regions, highlighting disparities in the continuity of vaccination services. It ranged from as low as 26.8% (95% CI: 20.1 - 34.8) in the Far North region to 75% (95% CI: 53.6 - 71.2) in the Douala region (Figure S3). As Penta3 timeliness is a critical indicator of both service delivery efficiency and adherence to the recommended immunization schedule, these variations suggest systemic challenges in ensuring timely completion of multi-dose vaccines. Poor performance on this indicator may reflect missed opportunities, delayed follow-up, or inequities in access to care.

Figure 1. Percentage of children who received vaccine earlier, on time, or vaccination delayed among children aged 12 to 35 months, MICS 2014, Cameroon.

2) Timely and completeness among children aged 12 to 35 months

Among the surveyed children, 66.1% (956/1447) (95% 63.6 - 68.5 CI = 63.6 - 68.5) were completely vaccinated on cards seen of all key vaccines (Table 1), among which only 11.3% (108/956) (95% CI = 9.4 - 13.5) received vaccine on time (Table 1). Among participants with cards seen, 1334 (92.2%) received week-6 vaccine, reflecting high contact rate with health facility after birth (Table 1). Timeliness and completeness for these antigens were generally above 80%. However, when focusing specifically on Penta3, only 56.7% (1255 children) had received the dose, and among them, just 46.1% were both timely and complete. While more than 60% of children received BCG, only 27% received it within the recommended time frame i.e., from birth to less than one week, indicating a significant proportion of delayed BCG administration.

Table 1. Percentage of children fully vaccinated and, who received vaccine on time among children aged 12 to 35 months, MICS 2014, Cameroon.

Vaccines

N = 1447*

#children who received the vaccine dose or

in the indicated characteristic (%)

n (%) children completely vaccinated

and timely in vaccine administration

BCG

1396 (63.0)

377 (27)

Polio 0

1283 (57.9)

387 (30.1)

Polio 1

1403 (63.4)

492 (35)

Polio 2

1347 (60.8)

488 (36.2)

Polio 3

1256 (56.7)

630 (50)

Penta1

1403 (63.4)

547 (39)

Penta2

1350 (60.9)

630 (47)

Penta3

1255 (56.7)

584 (46.1)

Pneumo 1

1357 (61.3)

548 (40.3)

Pneumo 2

1307 (59.0)

619 (47.4)

Pneumo 3

1224 (55.3)

575 (47)

Measles 1

1119 (50.5)

585 (52.3)

Yellow fever

1115 (50.4)

539 (48.3)

All antigens**

956/1447 (66.1%)

(95% CI = 63.6 - 68.5)

108/956 (11.3)

(95% CI = 9.4 - 13.5)

Week-6 vaccination++

1334 (92.2)

324 (24.5%)

Zero dose 1+

767 (34.6)

NA

Zero dose 2***

44 (2)

NA

Timely-and-Complete

vaccination coverage

OPV1-3

1230

959 (78)

PENTA1-3

1336

959 (71.5)

PCV1-3

1191

959 (80)

Legend: *the sample of children aged 12 to 35 months who had home-based records, with at least one vaccination date within HBR; **for 12 to 35 months children, those who received, on cards seen, BCG, OPV0-1-3; PENTA1-3, PCV1-3, Measles, and YF; +children who received none of the antigens (among those surveyed; n = 2214); *** children (among those surveyed) who never received penta1; ++ rate of accessibility: frequency of children who received week 6 vaccines: penta1, opv1, pcv1 among card seen and dates. NA: not applicable.

2.4. MOV Indicators

2.4.1. Overall MOV Prevalence and Age Category

Among children with cards seen (12 to 35 months) with at least one vaccination date (1447), 1307 (90.3%, 95% CI = 87% - 92%) experienced one or more MOV for simultaneous vaccines (Table 2). Among those who experienced an MOSV, 12.3% (161/1307) returned to health facilities to receive all previous missed vaccines, before the survey started. In contrary, 759 (759/1307 = 58.1%) did not come back to health facilities to catch-up the previously missed vaccines (Table 2). The proportion of children who remained with previous missed doses not all received (Some But not all corrected) was 29.6% (computed as (1307-759-161)/1307), and 95% CI = (27.1; 32.1) (data not tabulated).

In the first year of life (12 to 23 months), 90.9% of children experienced at least one MOV for simultaneous vaccines (MOSV), while 88.5% was found in the second year (24 - 35 months) of life (Table 2). However, there was no significant difference with the prevalence of MOV in the first year of life and the second year of life (p-value = 0.2). In addition, female children and male children experiences MOV the same as the difference in proportions was not statistically significant (p = 0.2) (Table 2). With regards to this nonexistence of difference, the following results are based on the whole sample.

We adjusted the MOSV prevalence by region using a simple meta-analysis of proportions:90% (95% CI = 84% - 94%) of overall MOV for simultaneous vaccines among which 61% (95% CI = 53% - 69%) were MOSV uncorrected, and only 12%; 95% CI = 8% - 16% had all the MOSV corrected before the survey began (Table 2).

Table 2. Overall MOV prevalence (raw and adjusted) by age category, and regions, and residence; Cameroon MICS, 2014.

Had MOSV (%)

Had MOSV only

uncorrected (%)

Had MOSV all

corrected (%)

Characteristic

Overall

YES

NO

YES

NO

YES

NO

MOV

N = 1447

N = 1307

N = 140

p

N = 759

N = 688

p

N = 161

N = 1286

p

Raw prevalence

(90.3)

(58.07)

(12.3)

Adjusted prevalence*

90

(95 CI = 84 - 94)

61

(95 CI = 53 - 69)

12;

95 CI = 8 - 16

Age category

(months)

0.2

0.4

0.8

12 to 23

1073

976 (91)

97 (9.0)

560 (57.3)

513 (48)

122 (12.5)

951 (89)

24 to 35

374

331 (89)

43 (11)

199 (60.1)

175 (47)

39 (11.7)

335 (90)

Childs sex

>0.9

>0.9

>0.9

1

758

684 (90)

74 (9.8)

397 (58.0)

361 (48)

85 (12.4)

673 (89)

2

689

623 (90)

66 (9.6)

362 (58.1)

327 (47)

76 (12.2)

613 (89)

Regions; n

0.005

<0.001

<0.001

Adamaoua

149

140 (94)

9 (6.0)

63 (45)

86 (58)

24 (17.1)

125 (84)

Centre (No Yaounde)

135

126 (93)

9 (6.7)

72 (57.1)

63 (47)

10 (7.9)

125 (93)

Douala

128

122 (95)

6 (4.7)

82 (67.2)

46 (36)

5 (4.0)

123 (96)

East

140

115 (82)

25 (18)

73 (63.4)

67 (48)

19 (16.5)

121 (86)

Far-North

138

117 (85)

21 (15)

46 (39.3)

92 (67)

30 (25.6)

108 (78)

Littoral (No Douala)

99

91 (92)

8 (8.1)

66 (72.5)

33 (33)

7 (7.7)

92 (93)

North

164

143 (87)

21 (13)

77 (53.8)

87 (53)

28 (19.6)

136 (83)

North-West

112

101 (90)

11 (9.8)

63 (62.3)

49 (44)

11 (10.8)

101 (90)

West

109

100 (92)

9 (8.3)

64 (64)

45 (41)

7 (7.0)

102 (94)

South

65

60 (92)

5 (7.7)

31 (51.7)

34 (52)

9 (15)

56 (86)

South-West

95

87 (92)

8 (8.4)

60 (69)

35 (37)

6 (6.8)

89 (94)

Yaounde

113

105 (93)

8 (7.1)

62 (59)

51 (45)

5 (4.7)

108 (96)

Residence; n

0.15

0.02

<0.001

1 = Urban

718

657 (92)

61 (8.5)

402 (61.1)

316 (44)

57 (8.6)

661 (92)

2 = Rural

729

650 (89)

79 (11)

357 (54.9)

372 (51)

104 (16)

625 (86)

Residence others;

n

0.072

0.05

<0.001

1 = Yaounde

and Douala

241

227 (94)

14 (5.8)

144 (63.4)

97 (40)

10 (4.4)

231 (96)

2 = Other towns

477

430 (90)

47 (9.9)

258 (60)

219 (46)

47 (11)

430 (90)

3 = Rural areas

729

650 (89)

79 (11)

357 (55)

372 (51)

104 (16)

625 (86)

*adjusted using a meta-analysis of proportions of MOV among regions; p: p-value for the chi-squared test or Fisher Exact test for qualitative variables, and Wilcoxon-Mann-Whitney for group mean comparison; MOSV: MOV for simultaneous vaccines; the sum of MOSV uncorrected and MOSV all corrected, taken away from the Had MOSV is the estimate of the “Some BUT not all corrected”.

2.4.2. Overall MOV Raw Prevalence and MICS Variables

1) Across regions

MOSV and sub-indicators varied significantly across regions (p < 0.0001) (Table 2). Among those who experienced an MOSV in those regions, only uncorrected MOSV was more than a half of those who experienced MOV. Indeed, in the Littoral (without Douala) region were 92% of children had at least one vaccine missed, 72.5% (i.e., 66 children out of 99 who experienced simultaneous MOV) did not correct their MOSV before the survey started (Table 2). Uncorrected MOSV ranged from 39.3% (in the Far North) to 72.5% in Littoral (without Douala), and consequently in very few proportions of previous missed vaccines were administered in Douala (4%) (Table 2). Although MOSV proportions did not differ significantly between place of residence (p = 0.15), there was a change in the uncorrected MOSV prevalence across residence place. Indeed, children within the urban area had 61.1% of MOV uncaught, and 55% in the rural areas, and the difference in proportions was highly significant (p ≤ 106) (Table 2). In addition to that, children in the rural area (16%) were more likely to correct their MOV than those in the urban area (8.6%) and the difference was highly significant (p < 0.001) (Table 2). When disaggregating place of residence by including Yaoundé and Douala, and other towns as urban areas, we found a significant difference in all MOV indicators (Table 2).

2) Regarding mothers education

In the same as the MOSV prevalence was significantly different across mother’s education, there was also a significant increase in the prevalence of uncorrected MOSV while moving from mothers with no education to those in the highest education (p < 0.001) (Table 3). In contrast, proportion of children with all corrected MOSV decreased significantly from the highest education level to below. Indeed, half of the children who experienced at least one MOSV at the lowest education level had their MOSV all corrected before the survey started (Table 3). Similar results were found in the household head education level (Table 3), as well as for the wealth index. Indeed, MOV for simultaneous vaccine increased with the wealth index (p < 0.001). There was a difference in proportion of MOSV among children whose mothers experienced more than four prenatal consultations than those below (p < 0.001) (Table 3).

Table 3. Overall raw MOV prevalence by household and child’s characteristics; Cameroon MICS, 2014.

Had MOSV (%)

Had MOSV only

uncorrected (%)

Had MOSV all

corrected (%)

Characteristics

Overall

YES

NO

YES

NO

YES

NO

N = 1447

N = 1307

N = 140

p

N = 759

N = 688

p

N = 161

N = 1286

p

Education*

<0.001

<0.001

<0.001

Never

274

229 (84)

45 (16)

111 (48.4)

163 (59)

56 (24.4)

218 (80)

Primary

557

503 (90)

54 (9.7)

275 (54.6)

282 (51)

63 (12.5)

494 (89)

Secondary

554

518 (94)

36 (6.5)

329 (63.5)

225 (41)

39 (7.5)

515 (93)

High

62

57 (92)

5 (8.1)

44 (77.2)

18 (29)

3 (5.2)

59 (95)

Wealth index

<0.001

0.002

<0.001

Very poor

198

164 (83)

34 (17)

80 (48.7)

118 (60)

38 (23.1)

160 (81)

Secondary

327

291 (89)

36 (11)

158 (54.3)

169 (52)

52 (17.8)

275 (84)

Middle

299

264 (88)

35 (12)

153 (58)

146 (49)

26 (9.8)

273 (91)

Rich

345

323 (94)

22 (6.4)

190 (58.8)

155 (45)

30 (9.2)

315 (91)

Richest

278

265 (95)

13 (4.7)

178 (67.2)

100 (36)

15 (5.6)

263 (95)

Education**

0.047

<0.001

0.0001

Never

249

213 (86)

36 (14)

97 (45.5)

152 (61)

44 (20.6)

205 (82)

Primary

575

518 (90)

57 (9.9)

295 (56.9)

280 (49)

60 (11.6)

515 (90)

Secondary

517

476 (92)

41 (7.9)

294 (61.7)

223 (43)

53 (11.1)

464 (90)

High

101

95 (94)

6 (5.9)

71 (74.7)

30 (30)

4 (4.2)

97 (96)

Missing

5

5

0 (0)

2 (40)

3 (60)

0 (0)

5

Place of delivery

0.03

0.06

<0.001

Respondent’s home

378

332 (88)

46 (12)

163 (49.1)

215 (57)

68 (20.4)

310 (82)

Other home

43

33 (77)

10 (23)

19 (57.5)

24 (56)

4 (12.1)

39 (91)

Public hospital

342

315 (92)

27 (7.9)

191 (60.6)

151 (44)

24 (7.6)

318 (93)

Public health center

(CSI/CS/PMI/Dispensary)

264

240 (91)

24 (9.1)

144 (60)

120 (45)

31 (13)

233 (88)

District Medical Center (CMA)

35

30 (86)

5 (14)

16 (53.3)

19 (54)

7 (23.3)

28 (80)

Other public medical facility

6

6

0 (0)

3 (50)

3 (50)

0 (0)

6

Private non-religious hospital

45

42 (93)

3 (6.7)

24 (57.1)

21 (47)

4 (9.5)

41 (91)

Private faith-based hospital

105

96 (91)

9 (8.6)

62 (64.6)

43 (41)

10 (10.4)

95 (90)

Private non-religious clinic

54

51 (94)

3 (5.6)

33 (64.7)

21 (39)

3 (5.8)

51 (94)

Faith-based/missionary health center or dispensary

138

131 (95)

7 (5.1)

87 (66.4)

51 (37)

8 (6.1)

130 (94)

Medical office/private practice

6

6

0 (0)

4 (66.6)

2 (33)

0 (0)

6

Other private medical facility

12

10 (83)

2 (17)

6 (60)

6 (50)

1 (0.1)

11 (92)

Don’t Know

7

4 (57)

3 (43)

0 (0)

7

1 (25)

6 (86)

Missing

12

11 (92)

1 (8.3)

7 (63.6)

5 (42)

0 (0)

12

Mode of delivery

0.5

0.3

0.4

1 = Cesarian

45

43 (96)

2 (4.4)

30 (69.8)

15 (33)

2 (4.6)

43 (96)

2 = No cesarian

965

887 (92)

78 (8.1)

543 (61.2)

422 (44)

86 (9.7)

879 (91)

9

9

8 (89)

1 (11)

4 (50)

5 (56)

0 (0)

9

Unknown

428

369

59

182

246

73

355

Skilled birth attendance

0.5

0.5

0.001

Medecins

216

200 (93)

16 (7.4)

119 (59.5)

97 (45)

15 (7.5)

201 (93)

Nurse/Midwife

727

669 (92)

58 (8.0)

405 (60.5)

322 (44)

61 (9.1)

666 (92)

Assistant nurse

325

305 (94)

20 (6.2)

190 (62.3)

135 (42)

36 (11.8)

289 (89)

Nursing aide/Auxiliary nurse

78

68 (87)

10 (13)

45 (66.1)

33 (42)

8 (11.7)

70 (90)

Traditional birth attendant

109

90 (83)

19 (17)

48 (53.3)

61 (56)

21 (23.3)

88 (81)

Community health worker

13

12 (92)

1 (7.7)

9 (75)

4 (31)

1 (8.3)

12 (92)

Prenatal consultation

<0.001

0.17

0.08

More than 4 = 0

677

639 (94)

38 (5.6)

392 (61.3)

285 (42)

63 (9.8)

614 (91)

Less 4 = 1

637

562 (88)

75 (12)

322 (57.3)

315 (49)

74 (13.1)

563 (88)

NA

133

106

27

45

88

22.6

109

*Mother’s education level; **Head of Household education level; NA: missing responses; p: p-value for the chi-squared test or Fisher Exact test for qualitative variables, and Wilcoxon-Mann-Whitney for group mean comparison; MOSV: MOV for simultaneous vaccines; the sum of MOSV uncorrected and MOSV all corrected, taken away from the Had MOSV is the estimate of the “Some BUT not all corrected”.

3) Regarding place of birth and prenatal consultation

Regarding child’s place of birth, the highest proportion of children who corrected their MOV was found in CMA and significant difference was found between all places of birth (p < 0.001) (Table 3). Among children who experienced an MOV, we found significant difference in proportion of those who caught their vaccines with the highest proportion for children born traditional birth attendant (Table 3). Indeed, there was 94% of MOV in children from four prenatal consultation against 88% in the opposite. In addition, uncorrected MOV differed slightly of 7% among those from less than four prenatal consultations than the opposite group, and this difference was highly significant (p = 0.007) (Table 3).

4) MOV with delayed dose, mothers age, domestic violence, vaccination contacts

According to delayed vaccination, and far as Penta 3 is concerned, we found significant difference between MOV uncorrected between those who delayed Penta 3 dose and those who did not p < 0.001) (Table S3). For the mother’s social life indicator like domestic violence, we found an increase of proportions with the increase of violence scores. Indeed, MOV prevalence was more pronounced in the highest quartile score, and the differences were significant (p = 0.034) (Table S3). This indicates that children born to mothers affected by domestic violence are less likely to update their vaccination status, as they are more prone to experiencing missed opportunities for vaccination (MOV) for any vaccine.

Moreover, 93% (657/710) of children who had vitamin A contact six months before the survey started, experienced MOV for simultaneous vaccines. Following mother’s age category found in the MICS dataset, there was no significant difference of MOV proportions across ae category (p > 0.05) (Table S2). In contrary, we used different coding of age category and found that children born to mother less than 25 years old were more likely to return to health facility (p < 0.001) (Table S3). Religion and vitamin A contact had significant difference in the proportions of MOV (Table S2). Indeed, children who never had vitamin contact had 0.88 probability of experiencing an MOV (Table S3).

2.4.3. MOV by Dose and Percentage of Vaccination Dates with MOV

Among children who were eligible for a dose, MOV occurred in 4% to 57% of them (Table 4). Indeed, MOV for Pneumococcal-conjugate-vaccine (PCV1) at 6-week was 57.1% following by the yellow fever with 53% of children who experienced an MOV among 939 eligible children in the sample. Among them, more than 90% (465/498) did not have chance to be vaccinated from previous missed dose before the survey commenced. Birth doses revealed 52.87% of MOV for OPV0. In the same line, more than 85% of children left without receiving them before the survey. Among those who experienced MOV for Penta3, i.e., 287 (23.7%), 160 (55.8%) did not come back to the health facility to receive previous missed vaccines (Table 4).

Table 4. Prevalence of dose-based Missed Opportunities for Vaccination (MOV) among children aged 12 to 35 months, Cameroon MICS 2014.

Vaccine

doses

Eligible

children*

# Had

MOV

% Had

MOV

# Had

Uncorrected MOV

% Had

Uncorrected MOV

# Had

corrected MOV

% Had

corrected MOV

Birth doses

BCG

1413

56

3.96

50

89.29

6

10.71

OPV0

1411

746

52.87

652

87.4

81

10.86

6-week doses

OPV1

1402

103

7.35

99

96.12

4

3.88

PENTA1

1387

570

41.1

529

92.81

41

7.19

PCV1

1392

795

57.11

99

12.45

68

8.55

10-week doses

OPV2

1321

106

8.02

80

75.47

26

24.53

PENTA2

1323

271

20.48

162

59.78

109

40.22

PCV2

1281

360

28.1

80

22.22

167

46.39

14-week doses

OPV3

1214

174

14.33

119

68.39

55

31.61

PENTA3

1211

287

23.7

160

55.75

127

44.25

PCV3

1286

389

30.25

119

30.59

215

55.27

9-months doses

MCV1

894

49

5.48

43

87.76

6

12.24

YF

939

498

53.04

465

93.37

33

6.63

*Number of children who had at least one vaccination visit when they were eligible for the dose, meaning they reached the required age and the required minimum time had elapsed since earlier doses in the series; BCG (Bacillus Calmette-Guérin); Polio vaccines: Oral Polio Vaccine at birth (OPV), Pentavalent vaccine (DTP-HepB-Hib1-3), Pneumococcal Conjugate Vaccine (PCV) (e.g., PCV1-3), Measles-containing vaccines: Measles-Rubella (MR or MCV1); YF: yellow fever.

The percentage of vaccination visits resulting in an MOV varied by dose, ranging from 4.6% for BCG to 47.4% for the yellow fever vaccine (Table S4). For Penta 3, around 21% of vaccination visits led to MOV, while 26% of visits resulted in missed opportunities for the third dose of the Pneumococcal Conjugate Vaccine (PCV). Overall, out of 6535 vaccination visits, 44.24% included at least one missed vaccine dose. Additionally, the frequency of missed doses was approximately one for every 1.56 visits to the health facility (Table S4).

2.4.4. Logistic Regression and Decision Tree

1) Association between variables and All uncorrected MOSV

Given the differences observed in Table 2, Table 3, and Table S3, results from the logistic regression identified the variable related to the total number of vaccination dates, as being strongly correlated with uncorrected MOSV, along with the delayed dose status of Penta3, and the regions of Far-North and South, to which we added the variable child’s sex. These variables were used to construct the decision tree shown in Figure S4, although only vaccination status emerged as the sole classification variable. Additionally, we included the sex variable through logistic regression among those selected in the final model.

The decision tree (Figure S4) revealed that the number of vaccination contacts is a strong predictor missed opportunities for simultaneous vaccination uncorrected. Among children with fewer than 5 contacts, 73% had uncaught MOV, meaning they never received the previous missed doses, while only 27% eventually caught up. This group accounted for 31% of the sample. In contrast, among those with 5 or more contacts, only 36% had MOSV uncorrected, and 64% were vaccinated later after experiencing previous missed doses. These children represented 69% of the total sample (Figure S4). This pattern demonstrates that children with fewer contacts are significantly more likely to remain unvaccinated, highlighting the importance of maintaining consistent engagement with immunization services through sensitization on the importance of vaccination attending. Strategies to improve follow-up and ensure repeated contact could play a key role in reducing persistent missed opportunities, and vitamin A contact could be alternatives.

2) Interaction between child’s sex and variables

Overall (for boys and girls), children with fewer than five vaccination dates were less likely to have uncorrected (MOSV compared to those with more than five contacts (OR = 0.29; 95% CI = 0.22 - 0.39) (Table 5). Furthermore, children residing in the Far-North region faced an increased risk of experiencing an MOSV, with an odds ratio of 1.86 compared to those in the Adamaoua region, and this result was statistically significant (p = 0.03). Similarly, children in Littoral (excluding Douala) and South-West regions demonstrated comparable risks, as their odds ratios were above 1 and the 95% confidence intervals did not include 1 (Table 5).

Table 5. Uncorrected MOSV and its association with variables across child’s sex in Cameroon MICS, 2014.

Overall;

12 - 35 m

95%

Confidence

Intervals

Boys

95%

Confidence

Intervals

Girls

95%

Confidence

Intervals

N = 1232*

Boys;

n (%)

Girls;

n (%)

All Uncorrected MOSV

705

370 (52)

335 (48)

Regression terms

Overall

Odds

ratios

(OR)

Low

High

p-value

Odds

ratios

(OR)

Low

High

p-value

Odds

ratios

(OR)

Low

High

p-value

Adamaoua

108

56 (52)

52 (48)

1.00

Centre (No Yaounde)

124

70 (56)

54 (44)

1.54

0.89

2.66

0.12

2.11

0.95

4.69

0.07

1.25

0.56

2.77

0.59

Douala

125

51 (41)

74 (59)

1.52

0.87

2.64

0.14

2.35

1.01

5.62

0.05

1.30

0.62

2.75

0.49

Far-North

107

54 (50)

53 (50)

1.86

1.06

3.30

0.03

East

88

44 (50)

44 (50)

1.00

0.55

1.81

0.99

Littoral (No Douala)

95

57 (60)

38 (40)

1.87

1.03

3.42

0.04

1.57

0.70

3.53

0.27

3.13

1.22

8.69

0.02

North

133

85 (64)

48 (36)

1.08

0.63

1.84

0.78

North-West

104

55 (53)

49 (47)

1.26

0.71

2.23

0.43

West

102

48 (47)

54 (53)

1.44

0.82

2.57

0.21

2.26

0.96

5.43

0.06

South

58

29 (50)

29 (50)

1.13

0.57

2.21

0.73

South-West

81

42 (52)

39 (48)

1.95

1.05

3.68

0.04

2.74

1.09

7.31

0.04

Yaounde

107

56 (52)

51 (48)

1.09

0.62

1.92

0.75

Total vaccination dates (more than 5)

934

486 (52)

448 (48)

1

Less than 5

298

161 (54)

137 (46)

0.29

0.22

0.39

<106

0.29

0.20

0.44

<106

0.28

0.18

0.43

<103

Delayed Penta3/NO

848

435 (51)

413 (49)

1

Delayed Penta3/YES

384

212 (55)

172 (45)

0.68

0.52

0.89

<106

0.54

0.37

0.77

<106

0.86

0.58

1.30

0.48

*The regression with interaction was ran on 1232 participants out of 1447, because missing values on variables were not allowed in the modelling process. Indeed, these are the variables that were retained during the Stepwise regression analysis, which required complete data in the estimation process.

Notably, girls were found to be at higher risk of experiencing uncorrected MOSV in Littoral (excluding Douala) (p = 0.02) (Table 5). Additionally, while children receiving Penta3 doses very late exhibited a significantly reduced risk of uncaught vaccines (p < 0.001), this effect was notably significant only among boys (p < 0.001) (Table 5).

3. Discussion

This study highlights the value of examining vaccination timeliness, completeness, and missed opportunities for vaccination (MOV) together to gain a comprehensive understanding of immunization program performance and quality. While completeness measures whether a child eventually receives all vaccines, timeliness assesses whether these are administered at the appropriate ages, and MOV reflects systemic inefficiencies, when eligible children interact with health services but do not receive due vaccines. With new MICS surveys planned soon, it is essential to have methodological benchmarks, which justify the importance of this work, as it can help guide the development of future survey reports. Though not intended to guide current decisions, the methodology can be adapted to recent surveys and facility-based studies, enhancing the evaluation of immunization strategies in similar settings. Through a survey conducted in Cameroon more than ten years ago, we developed a statistical analysis plan aimed at generating estimates on missed opportunities for vaccination (MOV), to fill the critical knowledge gap on MOV in the country.

Only 65.3% of children had vaccination cards with dates, well below the WHO benchmark of ≥90% for quality monitoring [36] [37]. By 2018, this had improved to 75.2% [38]. Complete vaccination coverage in 2014 was just 66.1%, compared to 70.4% in 2018 [20]. Coverage dropped significantly around the 6 - 14 weeks visits and again at 9 months, especially for yellow fever and measles vaccines. Timeliness rates were below 80%, with only 46.1% of children receiving Penta3 on time. BCG and birth-dose polio were particularly delayed. Vaccination at week 14, particularly Penta3, is an indicator of good vaccination coverage, and this appears to be strongly dependent on the level of access to health facilities after a child’s birth, which is also reflected by Penta1 coverage.

MOV prevalence was alarmingly high in 2014: nine out of ten children experienced MOSV. By 2018, this had improved, with three out of four children affected [20], i.e., a statistically significant reduction (p < 0.001). Specific antigens were disproportionately affected by MOV: it ranged from 53.04% (for yellow fever) to 57.1% for PCV1. Many children failed to catch up with previous missed doses. For instance, over 75% of oral polio doses were still overdue at the time of the survey. The 2018 DHS similarly reported high MOV for yellow fever (91.1%) and lower levels for oral polio vaccine [20]. Uncorrected MOSV in 2014 and 2018 were 61%, and 67%, respectively; highly above a pooled estimate of 15% [6% - 24%] of uncorrected MOSV in Africa [28].

These figures suggest that from 2014 to 2023, many children remained un- or under-protected against preventable diseases, contributing to recent epidemic resurgences. Despite relatively high coverage for BCG (93%) and Penta1 (81%) in 2023, other antigens remained below 85% especially, yellow fever and MCV1 coverage ranged between 67% and 71% [1] [39]. Even for BCG, delays were common, undermining its effectiveness [17]. These trends reflect persistent challenges in follow-up, access, and system responsiveness.

In addition to known predictors like maternal education, socioeconomic status, and residence [22] [40], this study found that regional residence, delays in Penta3, and the total number of recorded vaccination dates, as significant predictors of a child remaining unvaccinated over time after missing doses. Importantly, stratified analysis revealed gender-based differences, suggesting the need for regional and sex-specific targeting.

We found an apparent relationship between maternal exposure to domestic violence and MOV. The WHO recognizes domestic violence as a major mental health risk, often leading to post-traumatic stress disorder, which affects approximately 63.8% of women [41]-[43]. We observed that the likelihood of MOSV increased significantly with the level of domestic violence faced by the mother. First, according to current literature, children born to mothers facing post-partum mental health are more likely to be under vaccinated. Studies in high-income settings have shown that maternal mental illness is linked to lower childhood vaccination uptake and reduced adherence to recommended schedules, with children of mothers with common mental disorders having lower odds of being vaccinated at later ages compared to children of mothers without mental health conditions [44]. Third, intimate partner violence (IPV) and associated distress can impair caregiver capacity to manage complex schedules, prioritize preventive care, or navigate barriers such as travel, time constraints, and social isolation. This reduced capability can increase the risk of uncorrected MOV, where missed vaccines are not later caught up. Conceptually, IPV contributes both to psychosocial stress and structural constraints that jointly undermine optimal vaccination behavior. Second, violence and its psychological sequelae may undermine maternal health-seeking behavior, diminishing engagement with preventive services even when contact with health systems occurs. For example, cross-sectional analyses indicate that IPV can contribute to reduced utilization of maternal and child health services such as antenatal care and institutional delivery, which are key platforms for ensuring timely vaccination. To address these interlinked risks, it is essential to develop and deploy tools that simultaneously track vaccination status and underlying social vulnerability factors, such as maternal exposure to domestic violence and mental distress. Integrating these dimensions into routine monitoring systems can enable earlier identification of children at risk of uncorrected MOV and support targeted, proactive interventions to sustain high and equitable vaccination coverage.

4. Strengths and Limitations

This study contributes an analytical framework that can guide expansion of survey modules to cover vaccination timing, caregiver mental health, and card availability. As far as card availability is concerned, results from MOV only infer to the sample of children with cards possession, reason why the study design was not accounted for [27]. However, we conducted regression analyses and compared results between weighted and unweighted estimates, but the direction of the effect did not change (Table S5). We did not cover all relevant indicators, which should be addressed in future MICS rounds. These include time-to-correct MOSV, predictors of MOV, equity assessments using MOV indicators, and models of intersectional analysis. Beyond individual and household factors, structural and contextual barriers play a critical role. Understanding why previous missed vaccines are not caught up can uncover health system delivery gaps and inform more effective, equitable strategies [45]-[48].

Regression analyses identified the total number of vaccination contacts as a key predictor of uncorrected MOSV. This indicates that, within our dataset, the model primarily distinguishes between children who followed the recommended vaccination schedule and those who failed to attend the expected number of visits. This implies that failure to return to the health facility is a critical driver of uncorrected MOSV. It underscores the need to understand barriers to follow-up, especially around the 9-month milestone, and tailor interventions accordingly.

5. Programmatic and Survey Implications

Findings from the analysis of missed opportunities for vaccination (MOV) can help improve the targeting of future immunization strategies and surveys. Specifically, results can guide the prioritization of deeper or more frequent data collection efforts in high-risk subgroups, including rural populations, low-income households, mothers with low education levels, and children attending health facility types with a high prevalence of MOSV [49]. Attention should also be given to children with only uncorrected MOSV, those who did not eventually catch up on their missed doses, as well as those born to caregivers facing mental health challenges.

Data disaggregated by district supports equity-focused interventions. Identifying common ages for delay can optimize survey design and clarify definitions of early, timely, and delayed doses for each antigen in the national immunization schedule. Household survey-based MOV assessment remains challenging, but investment in training and standardization is key. Future surveys should include health provider KAP modules to examine service quality drivers. Integrating service delivery components (e.g., growth monitoring, family planning, maternal mental health) into survey tools offers a fuller picture of system performance. Linking mental health and immunization is especially important in the post-partum period [42] [50]. Tracking MOV and timeliness over time helps refine indicators beyond coverage rates. This aligns with WHO and UNICEF recommendations to include MOV in national monitoring [51]. Such integration improves funding proposals, aligns with the Immunization Agenda 2030 (IA2030) goals, and enhances national strategy. MOV analysis disaggregated by sex, region, maternal education, and facility type exposes equity gaps. Intersectional analyses can guide gender-sensitive, context-specific strategies to reduce barriers to immunization.

6. Conclusion

Though based on MICS 2014, this study presents a lasting analytical model for addressing current immunization challenges. It provides essential insights into vaccination system performance and quality, enabling future survey refinement and evidence-based planning. Incorporating timeliness and MOV into national data systems strengthens immunization strategies and equity, improving program responsiveness and impact.

Contributions to the Literature

  • Analysis of Cameroon’s MICS 2014 reveals a very high prevalence of missed opportunities for vaccination (MOV), exposing critical immunization gaps not captured by standard coverage indicators;

  • Uncorrected MOV disproportionately affects rural populations, poorer households, and children of less-educated mothers, highlighting persistent population health inequities;

  • Vaccination timeliness and MOV indicators provide essential complementary metrics for public health monitoring and immunization policy;

  • Leveraging existing survey data offers a cost-effective approach to inform equity-oriented immunization planning and outbreak prevention in low-resource settings.

Authors’ Contributions

The first author has an interest in the secondary use of survey databases. SWY was trained on the use of the WHO survey manual; ZF came up with the idea; SWY developed the work plan, ran the data selection process, implementation of MOV guidelines in R, and wrote the manuscript.

Funding

None.

Ethical Considerations

Not required.

Data Availability

The data used in this study come from the 2014 Cameroon Multiple Indicator Cluster Survey (MICS). Access to the data was granted following a formal request submitted and approved through the official MICS website (https://mics.unicef.org). Data used are publicly available upon request and fully anonymized, in accordance with UNICEF’s data use policies. Ethical approval was not required for this study, as it is based on secondary data that are publicly available and fully anonymized, containing no identifiable personal information.

Acknowledgements

A special thank to Carolina Danovaro, WHO, immunization and Biology, Geneva Heart quarter, for providing suggestions and comments for improvement. My thanks to ADS Cabinet Cote d’Ivoire for the successful training receiving on the conduct and analysis of vaccination coverage survey, as well as the Online Survey Scholar Courses completed on the use of the WHO survey manual 2018 through the Geneva Learning Foundation initiatives. We are also grateful to the reviewers who provided thorough and more detailed suggestions for significant improvements to the content. We are also grateful to T-WHEYSTATS: Training more Women in Health and Statistics, Yaoundé, Cameroon, for the accompaniment in data analysis and editing.

Supplements

Figure S1. Flow chart of the participants from MICS 2014, Cameroon.

Figure S2. Cumulative coverage on cards seen with vaccination date among children aged 12 to 35 months.

Timeliness means percentage (proportion) of children who received vaccine within the window of opportunity (see Table S1). Dotted red line is the proportion of children with card possession that have vaccination dates (65.3%).

Figure S3. Penta3 vaccination timeliness among regions in children aged 12 to 35 months (N = 1447) Cameroon MICS, 2014.

Figure S4. Final decision tree for MOV with previous uncaught vaccines, Cameroon MICS, 2014.

Table S1. Vaccination timeliness (early, on time, and delayed) and window of opportunity according the Cameroon National schedule and WHO recommendations.

Vaccines

Early (days)

On time: window of opportunity (days): min-max

Late (days)

BCG

0 - 7

>7

OPV0

0 - 7

>7

MCV1

<270

270 - (270 + 28)

>298

YF

<270

270 - (270 + 28)

>298

ROTA1

<42

42 - 72.5

>72.5

ROTA2

<70

70 - 100.5

>100.5

PENTA1

<42

42 - 72.5

>72.5

PENTA2

<70

70 - 100.5

>100.5

PENTA3

<98

98 - 128.5

>128.5

OPV1

<42

42 - 72.5

>72.5

OPV2

<70

70 - 100.5

>100.5

OPV3

<98

98 - 128.5

>128.5

PCV1

<42

42 - 72.5

>72.5

PCV2

<70

70 - 100.5

>100.5

PCV3

<98

98 - 128.5

>128.5

Table S2. Sources of vaccination for antigens from Cameroon MICS, 2014.

Vaccination status

bcg

opv0

opv1

opv2

opv3

penta1

penta2

penta3

pcv1

pcv2

pcv3

mcv1

yf

Vaccinated with date = 1

1396

1283

1403

1347

1256

1403

1350

1255

1357

1307

1224

1119

1115

Vaccinated from recall = 2

7

5

6

5

5

5

5

7

8

6

6

13

14

Don’t know = 3

16

20

12

29

47

6

18

34

20

30

40

72

63

Total

1447

1447

1421

1447

1447

1447

1447

1447

1447

1447

1447

1447

1192

Total surveyed = 2214; 1447 with HBR i.e., 65.3% of card possession

Table S3. MOSV with delayed dose, mother’s age, domestic violence, vaccination contacts; Cameroon MICS, 2014.

Had MOSV (%)

Had MOSV uncorrected (%)

Had MOSV All corrected (%)

Characteristic

Overall

YES

NO

YES

NO

YES

NO

N = 1447

N = 1307

N = 140

p

N = 759

N = 688

p

N = 161

N = 1286

p

Penta 3 delayed status

0.4

<0.001

0.7

0 = NO

900

840 (93)

60 (6.7)

554 (62)

346 (38)

84 (9.3)

816 (91)

1 = YES

435

400 (92)

35 (8.0)

195 (45)

240 (55)

43 (9.9)

392 (90)

Missing

112

67

45

10

102

34

78

Domestic violence (in quartile)

0.034

0.7

>0.9

Q1

2

1 (50)

1 (50)

1 (50)

1 (50)

0 (0)

2

Q2

410

364 (89)

46 (11)

214 (58.8)

196 (48)

45 (12.3)

365 (89)

Q3

312

292 (94)

20 (6.4)

173 (59.2)

139 (45)

33 (11.3)

279 (89)

Q4

723

650 (90)

73 (10)

371 (57.0)

352 (49)

83 (12.8)

640 (89)

Grouped quartiles

0.068

0.5

0.8

Q1 + Q2

412

365 (89)

47 (11)

215 (59)

197 (48)

45 (12.3)

367 (89)

Q3

312

292 (94)

20 (6.4)

173 (59.2)

139 (45)

33 (11.3)

279 (89)

Q4

723

650 (90)

73 (10)

371 (57.0)

352 (49)

83 (12.8)

640 (89)

Household head religion

0.017

0.07

0.13

Catholic

543

500 (92)

43 (7.9)

296 (59.2)

247 (45)

56 (11.2)

487 (90)

Protestant

372

341 (92)

31 (8.3)

207 (60.7)

165 (44)

37 (10.8)

335 (90)

Other Christian

315

269 (85)

46 (15)

139 (51.6)

176 (56)

44 (16.3)

271 (86)

Muslim

101

90 (89)

11 (11)

48 (53.3)

53 (52)

8 (8.8)

93 (92)

Animist

116

107 (92)

9 (7.8)

69 (64.4)

47 (41)

16 (15)

100 (86)

Domestic violence

0.6

0.4

0.7

0

724

657 (91)

67 (9.3)

336 (51.1)

724

646 (98.3)

724

1

723

650 (90)

73 (10)

352 (54.1)

723

640 (98.4)

723

Women age (years)

26 (23 - 32)

26 (23 - 32)

25 (22 - 30)

0.2

26 (23 - 32)

26 (23 - 32)

0.7

26 (22 - 31)

26 (23 - 32)

0.069

Women age (years)

0.6

0.5

0.018

<25

575

514 (89)

61 (11)

311 (60.5)

264 (46)

55 (10.7)

520 (90)

25 - 44

852

774 (91)

78 (9.2)

439 (56.7)

413 (48)

100 (13)

752 (88)

≥44

20

19 (95)

1 (5.0)

9 (47.3)

11 (55)

6 (30)

14 (70)

Vitamine A status (6 months)

0.015

<0.001

<0.001

No upatke

657

576 (88)

81 (12)

288 (50)

369 (56)

100 (17.3)

557 (85)

Recent dose

710

657 (93)

53 (7.5)

430 (65.4)

280 (39)

53 (7.8)

657 (93)

Dose before the most recent

14

14

0 (0)

10 (71.4)

4 (29)

3 (21.4)

11 (79)

DontKnow

66

60 (91)

6 (9.1)

31 (51.6)

35 (53)

5 (8.3)

61 (92)

Age group (MICS 14 coding)

0.2

0.03

0.5

<20

128

115 (90)

13 (10)

57 (49.6)

71 (55)

14 (12.7)

114 (89)

20 - 34

1091

979 (90)

112 (10)

588 (60.0)

503 (46)

116 (11.8)

975 (89)

34 - 49

228

213 (93)

15 (6.6)

114 (53.5)

114 (50)

31 (14.6)

197 (86)

Total eligible vaccination date for any dose

<0.001

<0.001

<0.001

0; >=5 contacts

999

944 (94)

55 (5.5)

639 (67.7)

360 (36)

58 (6.1)

941 (94)

1; <5 contacts

448

363 (81)

85 (19)

120 (33.0)

328 (73)

103 (28.3)

345 (77)

p p-value for the chi-squared test or Fisher Exact test for qualitative variables, and Wilcoxon-Mann-Whitney for group mean comparison; MOSV: MOV for simultaneous vaccines; the sum of MOSV uncorrected and MOSV all corrected, taken away from the Had MOSV is the estimate of the “Some BUT not all corrected”.

Table S4. Percentage of visits with Missed Opportunities for Vaccination (MOV) for each dose, and for any dose (1+ doses), Cameroon MICS 2014.

Vaccine

doses

Total eligible

vaccination dates*

Vaccination

dates with

MOV

% vaccination

dates with

MOV

Overall vaccination

dates for any dose

#vaccination

dates with MOV

for any dose

% vaccination

dates with MOV

for any dose

Sum total

MOV for all

doses

MOV

rate

BCG

1572

72

4.58

OPV0

3813

804

21.09

OPV1

1685

104

6.17

OPV2

1530

111

7.25

OPV3

1455

188

12.92

PENTA1

2957

586

19.82

6537

2892

44.3

4183

0.64

PENTA2

1774

287

16.18

PENTA3

1517

316

20.83

PCV1

3508

847

24.14

PCV2

1882

386

20.51

PCV3

1609

425

26.41

YF

1090

517

47.43

MCV1

933

57

6.11

*Total number of vaccination date for which children were eligible for a dose.

Table S5. Comparison between unweighted and weighted estimates from the regression analyses of MICS 2014, Cameroon.

Unweighted regression with sex interaction

Survey design accounted for within sex intrecation model

term

estimate

stderror

statistic

pvalue

conflow

confhigh

term

estimate

stderror

statistic

pvalue

conflow

confhigh

(Intercept)

1.418

0.294

1.189

0.235

0.798

2.544

(Intercept)

1.40

0.30

1.12

0.26

0.77

2.56

region_cod1:HL41

1.362

0.421

0.734

0.463

0.596

3.119

region_cod1:HL41

1.50

0.40

1.01

0.31

0.68

3.32

region_cod2:HL41

2.107

0.406

1.837

0.066

0.952

4.689

region_cod2:HL41

2.23

0.45

1.80

0.07

0.93

5.36

region_cod3:HL41

2.349

0.437

1.956

0.050

1.007

5.615

region_cod3:HL41

2.50

0.46

2.01

0.04

1.02

6.11

region_cod4:HL41

2.006

0.423

1.645

0.100

0.877

4.632

region_cod4:HL41

2.08

0.54

1.36

0.18

0.72

6.02

region_cod5:HL41

0.988

0.450

−0.026

0.979

0.406

2.386

region_cod5:HL41

0.91

0.47

−0.21

0.84

0.36

2.28

region_cod6:HL41

1.569

0.411

1.097

0.273

0.703

3.532

region_cod6:HL41

1.52

0.43

0.99

0.32

0.66

3.51

region_cod7:HL41

1.402

0.383

0.882

0.378

0.660

2.975

region_cod7:HL41

1.46

0.41

0.92

0.36

0.65

3.25

region_cod8:HL41

1.232

0.408

0.511

0.609

0.553

2.750

region_cod8:HL41

1.05

0.43

0.11

0.91

0.45

2.42

region_cod9:HL41

2.263

0.440

1.857

0.063

0.962

5.427

region_cod9:HL41

2.56

0.46

2.03

0.04

1.03

6.35

region_cod10:HL41

1.064

0.509

0.121

0.904

0.388

2.882

region_cod10:HL41

1.09

0.53

0.16

0.88

0.39

3.05

region_cod11:HL41

1.733

0.448

1.227

0.220

0.724

4.221

region_cod11:HL41

2.33

0.48

1.75

0.08

0.90

6.01

region_cod12:HL41

1.315

0.407

0.672

0.502

0.592

2.939

region_cod12:HL41

1.37

0.42

0.76

0.45

0.61

3.11

region_cod1:HL42

0.852

0.410

−0.391

0.696

0.379

1.902

region_cod1:HL42

1.00

0.43

−0.01

0.99

0.43

2.33

region_cod2:HL42

1.246

0.405

0.542

0.588

0.563

2.766

region_cod2:HL42

1.29

0.43

0.59

0.55

0.55

3.02

region_cod3:HL42

1.302

0.379

0.697

0.486

0.619

2.746

region_cod3:HL42

1.24

0.41

0.53

0.60

0.56

2.78

region_cod4:HL42

1.946

0.420

1.583

0.113

0.857

4.477

region_cod4:HL42

2.48

0.43

2.10

0.04

1.06

5.78

region_cod5:HL42

1.150

0.443

0.315

0.752

0.481

2.742

region_cod5:HL42

1.22

0.47

0.43

0.67

0.49

3.07

region_cod6:HL42

3.134

0.497

2.299

0.022

1.219

8.694

region_cod6:HL42

2.88

0.55

1.93

0.05

0.98

8.48

region_cod7:HL42

0.917

0.419

−0.208

0.835

0.401

2.085

region_cod7:HL42

0.82

0.50

−0.39

0.70

0.31

2.19

region_cod8:HL42

1.501

0.419

0.969

0.333

0.662

3.444

region_cod8:HL42

1.36

0.42

0.72

0.47

0.59

3.10

region_cod9:HL42

1.134

0.402

0.312

0.755

0.515

2.502

region_cod9:HL42

1.58

0.44

1.05

0.30

0.67

3.74

region_cod10:HL42

1.369

0.487

0.646

0.518

0.529

3.597

region_cod10:HL42

1.76

0.50

1.13

0.26

0.66

4.72

region_cod11:HL42

2.737

0.482

2.089

0.037

1.090

7.311

region_cod11:HL42

2.25

0.54

1.50

0.13

0.78

6.51

region_cod12:HL42

NA

NA

NA

NA

NA

NA

HL41:total_elig [T.1]

0.299

0.205

−5.875

0.000

0.199

0.446

HL41:total_elig1

0.27

0.24

−5.57

0.00

0.17

0.43

HL42:total_elig [T.1]

0.279

0.222

−5.738

0.000

0.179

0.429

HL42:total_elig1

0.25

0.26

−5.31

0.00

0.15

0.42

HL41:delayedpenta3 [T.1]

0.536

0.187

−3.346

0.001

0.371

0.772

HL41:delayedpenta31

0.55

0.21

−2.89

0.00

0.36

0.82

HL42:delayedpenta3 [T.1]

0.864

0.207

−0.705

0.481

0.576

1.300

HL42:delayedpenta31

0.73

0.25

−1.27

0.20

0.45

1.19

HL41 = male child; HL42 = female child; conflow-confhigh = lower and upper bounds of the estimate (logOR) 95% confidence interval.

Conflicts of Interest

None declared.

References

[1] World Health Organization. Immunization Coverage.
https://www.who.int/news-room/fact-sheets/detail/immunization-coverage
[2] GVAP. Immunisation in the Next Decade: 2021-2030 Strategy.
https://www.gavi.org/our-alliance/global-health-and-development/decade-vaccines-collaboration
[3] Clark, A. and Sanderson, C. (2009) Timing of Children’s Vaccinations in 45 Low-Income and Middle-Income Countries: An Analysis of Survey Data. The Lancet, 373, 1543-1549.[CrossRef] [PubMed]
[4] Vandelaer, J., Bilous, J. and Nshimirimana, D. (2008) The Reaching Every District (RED) Approach as a Way to Improve Immunization Performance. Bulletin of the World Health Organization, 86, Article No. 240.[CrossRef] [PubMed]
[5] World Health Organization. Methodology for the Assessment of Missed Opportunities for Vaccination.
https://www.who.int/publications/i/item/9789241512954
[6] Li, A.J., Tabu, C., Shendale, S., Sergon, K., Okoth, P.O., Mugoya, I.K., et al. (2020) Assessment of Missed Opportunities for Vaccination in Kenyan Health Facilities, 2016. PLOS ONE, 15, e0237913.[CrossRef] [PubMed]
[7] Rhoda, D.A., Prier, M.L., Clary, C.B., Trimner, M.K., Velandia-Gonzalez, M., Danovaro-Holliday, M.C., et al. (2021) Using Household Surveys to Assess Missed Opportunities for Simultaneous Vaccination: Longitudinal Examples from Colombia and Nigeria. Vaccines, 9, Article No. 795.[CrossRef] [PubMed]
[8] World Health Organization. Vaccination Coverage Cluster Surveys: Reference Manual.
https://www.who.int/publications/i/item/WHO-IVB-18.09
[9] Mansour, Z., Said, R., Brandt, L., Khachan, J., Rady, A., Fahmy, K., et al. (2018) Factors Affecting Age-Appropriate Timeliness of Vaccination Coverage among Children in Lebanon. Gates Open Research, 2, 71.[CrossRef] [PubMed]
[10] Masters, N.B., Wagner, A.L., Carlson, B.F. and Boulton, M.L. (2018) Vaccination Timeliness and Co-Administration among Kenyan Children. Vaccine, 36, 1353-1360.[CrossRef] [PubMed]
[11] Bloland, P. and MacNeil, A. (2019) Defining & Assessing the Quality, Usability, and Utilization of Immunization Data. BMC Public Health, 19, Article No. 380.[CrossRef] [PubMed]
[12] Patel, M.K., Scobie, H.M., Serhan, F., Dahl, B., Murrill, C.S., Nakamura, T., et al. (2024) A Global Comprehensive Vaccine-Preventable Disease Surveillance Strategy for the Immunization Agenda 2030. Vaccine, 42, S124-S128.[CrossRef] [PubMed]
[13] Fischer, T.K., Johannesen, C.K., Benschop, K.S.M., Berginc, N., Saxentoff, E.V., Huseynov, S., et al. (2024) Poliovirus Circulation in the WHO European Region, 2015-2022: A Review of Data from WHO’s Three Core Poliovirus Surveillance Systems. The Lancet Regional HealthEurope, 47, Article ID: 101104.[CrossRef] [PubMed]
[14] Ndwandwe, D., Nnaji, C.A. and Wiysonge, C.S. (2020) The Magnitude and Determinants of Missed Opportunities for Childhood Vaccination in South Africa. Vaccines, 8, Article No. 705.[CrossRef] [PubMed]
[15] Sowe, A., Namatovu, F., Cham, B. and Gustafsson, P.E. (2023) Missed Opportunities for Vaccination at Point of Care and Their Impact on Coverage and Urban-Rural Coverage Inequity in the Gambia. Vaccine, 41, 7647-7654.[CrossRef] [PubMed]
[16] Groene, E.A., Horvath, K.J., Yared, N., Mohammed, I., Muscoplat, M., Kuramoto, S., et al. (2021) Missed Opportunities for Human Papillomavirus Vaccination by Parental Nativity, Minnesota, 2015-2018. Public Health Reports®, 137, 867-877.[CrossRef] [PubMed]
[17] Dombou Zeufack, A.G., Noukeu Njinkui, D., Whegang Youdom, S. and Ateudjieu, J. (2023) Timeliness and Missed Opportunities for Vaccination among Children Aged 0 to 23 Months in Dschang Health District, West Region, Cameroon: A Cross-Sectional Survey. PLOS Global Public Health, 3, e0001721.[CrossRef] [PubMed]
[18] Adamu, A.A., Sarki, A.M., Uthman, O.A., Wiyeh, A.B., Gadanya, M.A. and Wiysonge, C.S. (2019) Prevalence and Dynamics of Missed Opportunities for Vaccination among Children in Africa: Applying Systems Thinking in a Systematic Review and Meta-Analysis of Observational Studies. Expert Review of Vaccines, 18, 547-558.[CrossRef] [PubMed]
[19] Nnaji, C.A., Wiysonge, C.S., Adamu, A.A., Lesosky, M., Mahomed, H. and Ndwandwe, D. (2022) Missed Opportunities for Vaccination and Associated Factors among Children Attending Primary Health Care Facilities in Cape Town, South Africa: A Pre-Intervention Multilevel Analysis. Vaccines, 10, Article No. 785.[CrossRef] [PubMed]
[20] Youdom, S.W., Njinkui, D.N., Nguefack-Tsague, G. and Ateudjieu, J. (2022) Missed Opportunities for Vaccination and Associated Factors among Children Aged 12-23 Months in Cameroon: Further Analyses of 2018 Cameroon Demographic and Health Survey. Health, 14, 1081-1103.[CrossRef]
[21] Fatiregun, A.A., Lochlainn, L.N., Kaboré, L., Dosumu, M., Isere, E., Olaoye, I., et al. (2021) Missed Opportunities for Vaccination among Children Aged 0-23 Months Visiting Health Facilities in a Southwest State of Nigeria, December 2019. PLOS ONE, 16, e0252798.[CrossRef] [PubMed]
[22] Rasmussen, C.E.H., Vedel, J.O., Jensen, A.M., Borges, I.D.S., Furtado, O., Meyrowitsch, D.W., et al. (2024) Implementation of the Vaccination Program in Guinea-Bissau: Coverage and Missed Opportunities for BCG at Birth. Vaccine, 42, Article 126056.[CrossRef] [PubMed]
[23] Kaboré, L., Meda, B., Médah, I., Shendale, S., Nic Lochlainn, L., Sanderson, C., et al. (2020) Assessment of Missed Opportunities for Vaccination (MOV) in Burkina Faso Using the World Health Organization’s Revised MOV Strategy: Findings and Strategic Considerations to Improve Routine Childhood Immunization Coverage. Vaccine, 38, 7603-7611.[CrossRef] [PubMed]
[24] Magadzire, B.P., Joao, G., Shendale, S. and Ogbuanu, I.U. (2017) Reducing Missed Opportunities for Vaccination in Selected Provinces of Mozambique: A Study Protocol. Gates Open Research, 1, 5.[CrossRef] [PubMed]
[25] NHDP National Health Development Plan (NHDP) 2021-2025. WHO. Regional Office for Africa.
https://www.afro.who.int/countries/cameroon/publication/national-health-development-plan-nhdp-2021-2025
[26] Wagai, J.N., Rhoda, D., Prier, M., Trimmer, M.K., Clary, C.B., Oteri, J., et al. (2021) Implementing WHO Guidance on Conducting and Analysing Vaccination Coverage Cluster Surveys: Two Examples from Nigeria. PLOS ONE, 16, e0247415.[CrossRef] [PubMed]
[27] World Health Organization. Vaccination Coverage Quality Indicators (VCQI).
https://www.technet-21.org/en/community/groups/293-vcqi
[28] Tamuzi, J.L., Katoto, P.D.M.C., Ndwandwe, D.E., Wiysonge, C.S. and Nyasulu, P.S. (2025) Prevalence of Missed Opportunities for Vaccination (MOV) Indicators among Children Aged 12-23 Months in Sub-Saharan African Countries: An Individual-Level Meta-Analysis of DHS and MICS National Household Data Surveys. Human Vaccines & Immunotherapeutics, 21, Article ID: 2510714.[CrossRef] [PubMed]
[29] cMYP Comprehensive Multi-Year Plan 2015-2019 on Immunization. Country Planning Cycle Database.
https://extranet.who.int/countryplanningcycles/planning-cycle-files/cameroon-comprehensive-multi-year-plan-2015-2019-immunization
[30] (2026) Normes et Standards du Programme Elargi de Vaccination au Cameroun |OMS| Bureau régional pour l’Afrique.
https://www.afro.who.int/fr/countries/cameroon/publication/normes-et-standards-du-pev-cameroun
[31] MICS Cameroon 2014 MICS Key Findings Report.
https://mics.unicef.org/news/cameroon-2014-mics-key-findings-report-released
[32] Wang, N. (2018) How to Conduct a Meta-Analysis of Proportions in R: A Comprehensive Tutorial.
[33] Daramola, T. and Szatkowski, L. (2023) Association between Women’s Experience of Domestic Violence and Childhood Vaccination in West Africa: Cross-Sectional Analysis of Demographic and Health Survey Data. PLOS ONE, 18, e0293900.[CrossRef] [PubMed]
[34] Santos, T.M., Cata-Preta, B.O., Victora, C.G. and Barros, A.J.D. (2021) Finding Children with High Risk of Non-Vaccination in 92 Low-and Middle-Income Countries: A Decision Tree Approach. Vaccines, 9, Article No. 646.[CrossRef] [PubMed]
[35] R Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing.
[36] GVAP Global Vaccine Action Plan.
https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/global-vaccine-action-plan
[37] UNICEF MICS Survey Tools and Guidance for Immunization Module.
https://mics.unicef.org/tools
[38] INS République Du Cameroun: Enquête Démographique et de Santé 2018. 2020, 2018.
[39] WHO-UNICEF. Estimates of National Immunization Coverage Available.
https://www.who.int/teams/immunization-vaccines-and-biologicals/immunization-analysis-and-insights/global-monitoring/immunization-coverage/who-unicef-estimates-of-national-immunization-coverage
[40] Salako, J., Bakare, D., Uchendu, O.C., Bakare, A.A., Graham, H. and Falade, A.G. (2024) Factors Associated with Immunization Status among Children Aged 12-59 Months in Lagelu Local Government Area, Ibadan: A Cross-Sectional Study. The Pan African Medical Journal, 47, Article No. 35.[CrossRef] [PubMed]
[41] World Health Organization (2005) WHO Multi-Country Study on Women’s Health and Domestic Violence against Women: Summary Report.
https://www.who.int/publications/i/item/9241593512
[42] Wake, G.E., Fitie, G.W., Ashenafi, B., Tadese, M. and Tessema, S.D. (2022) Magnitude and Determinant Factors of Postpartum Depression among Mothers Attending Their Postnatal and Vaccination Services at Public Health Institutions of Addis Ababa, Ethiopia. Frontiers in Public Health, 10, Article ID: 882205.[CrossRef] [PubMed]
[43] Desta, M., Memiah, P., Kassie, B., Ketema, D.B., Amha, H., Getaneh, T., et al. (2021) Postpartum Depression and Its Association with Intimate Partner Violence and Inadequate Social Support in Ethiopia: A Systematic Review and Meta-Analysis. Journal of Affective Disorders, 279, 737-748.[CrossRef] [PubMed]
[44] Kumari, P., Kumar, R. and Nagarajan, R. (2025) Examining Intimate Partner Violence as a Barrier to Childhood Immunization in India with Focus on Maternal and Child Factors. Scientific Reports, 15, Article No. 35248.[CrossRef]
[45] Kamal, A., Waseem, A., Siddiqa, M., Ijaz, M., Shakeel, A. and Iftikhar, S. (2023) Contextual Factors Influencing Incomplete Immunization and Investigation of Its Geospatial Heterogeneity in Pakistan: A Cross-Sectional Study Based on PDHS (2017-18). BMC Public Health, 23, Article No. 1620. [Google Scholar] [CrossRef] [PubMed]
[46] Adamu, A.A., Jalo, R.I., Habonimana, D. and Wiysonge, C.S. (2020) COVID-19 and Routine Childhood Immunization in Africa: Leveraging Systems Thinking and Implementation Science to Improve Immunization System Performance. International Journal of Infectious Diseases, 98, 161-165.[CrossRef] [PubMed]
[47] Sakas, Z., Hester, K.A., Ellis, A., Ogutu, E.A., Rodriguez, K., Bednarczyk, R., et al. (2023) Critical Success Factors for High Routine Immunisation Performance: A Qualitative Analysis of Interviews and Focus Groups from Nepal, Senegal, and Zambia. BMJ Open, 13, e070541.[CrossRef] [PubMed]
[48] Omuemu, V.O., Ogboghodo, E.O. and Erhunmwunsee, J. (2023) Missed Opportunity for Routine Childhood Vaccination in Urban and Rural Areas of Edo State, Nigeria: A Comparative Study. West Africa Journal of Medicine, 40, 312-320.
[49] Ogutu, E.A., Ellis, A.S., Hester, K.A., Rodriguez, K., Sakas, Z., Jaishwal, C., et al. (2024) Success in Vaccination Programming through Community Health Workers: A Qualitative Analysis of Interviews and Focus Group Discussions from Nepal, Senegal and Zambia. BMJ Open, 14, e079358.[CrossRef] [PubMed]
[50] Ijarotimi, O., Ijarotimi, I., Ubom, A., Sowemimo, O. and Orji, E. (2023) The Effect of Integration of Family Planning Education with Infant Vaccination Visits on the Uptake of Postpartum Family Planning in Ile-Ife, Nigeria. Journal of Obstetrics and Gynaecology, 43, Article ID: 2186774.[CrossRef] [PubMed]
[51] World Health Organization. Immunization Agenda 2030.
https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/ia2030

Copyright © 2026 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.